Joshua D Rosenblat has received research grant support from the Canadian Institute of Health Research (CIHR), Physician Services Inc (PSI) Foundation, Labatt Brain Health Network, Brain and Cognition Discovery Foundation (BCDF), Canadian Cancer Society, Canadian Psychiatric Association, Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M
In March 2024, FDA approved a new indication to reduce MACE in adults with established CV disease and overweight/obesity based on SELECT, marking the first obesity medication with a dedicated CV riskreduction label in this population
Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H
Heat stress attenuates free radical release in the isolated perfused rat heart
Personalized Approach: Genetic Testing and Smoking Susceptibility PlexusDx Precision Peptide Genetic Test analyzes genetic variants that influence dopamine-reward pathways and impulse control, including markers associated with addiction susceptibility
That's why what you eat on a GLP-1 matters so much